miR-210: A non-invasive biomarker for hypoxia-driven lung cancer diagnosis and therapy

Ahsas Goyal ¹, Muhammad Afzal ², Kavita Goyal ³

¹Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
²Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia.
³Department of Biotechnology, Graphic Era (Deemed to be University), Clement Town, Dehradun 248002, India.
⁴Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
⁵Department of Applied Sciences-Chemistry, NIMS Institute of Engineering & Technology, NIMS University Rajasthan, Jaipur, India.
⁶Department of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
⁷Department of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha 751030, India.
⁸Department of Chemistry, Chandigarh Engineering College, Chandigarh Group of Colleges-Jhanjeri, Mohali 140307 Punjab, India.
⁹Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
¹⁰Department of General Surgery, Consultant Head and Neck Surgical Oncology, Dr.D.Y.Patil Medical College, Hospital and Research Centre, Pimpri, Pune India.
¹¹Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf 72341, Saudi Arabia.
¹²Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
¹³Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

⁰Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.

Clinica Chimica Acta; International Journal of Clinical Chemistry +

|

March 3, 2025

View abstract on PubMed

Summary

MicroRNA-210 (miR-210) shows promise as a non-invasive biomarker for early lung cancer detection and a potential therapeutic target, especially in hypoxic tumors. Further research is needed to confirm its role in personalized medicine.

Area Of Science

Oncology
Molecular Biology
Biomarker Discovery

Background

Lung cancer remains a leading cause of cancer mortality globally, often diagnosed at late stages due to limitations of invasive procedures.
Tumor hypoxia, a hallmark of aggressive lung cancer, elevates hypoxia-inducible factors, which in turn increase microRNA-210 (miR-210) expression.
MiR-210 is implicated in promoting cancer cell survival, angiogenesis, and metastasis under hypoxic conditions.

Purpose Of The Study

To evaluate the potential of miR-210 as a non-invasive diagnostic and prognostic biomarker for lung cancer.
To explore the therapeutic implications of targeting miR-210 in hypoxic lung cancer.
To assess the feasibility of using miR-210 detection in biofluids for early cancer diagnosis.

Main Methods

Analysis of hypoxia-associated molecular signatures in lung cancer.
Detection of miR-210 levels in biofluids (serum, plasma) using liquid biopsy techniques.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for sensitive and specific miR-210 quantification.

Main Results

MiR-210 is identified as a stable and measurable biomarker in serum and plasma, suitable for non-invasive detection.
Established techniques like qRT-PCR enable sensitive and specific detection of miR-210, facilitating early diagnosis of hypoxic lung cancers.
MiR-210 demonstrates potential as a therapeutic agent by suppressing hypoxia-resistant genes, offering an alternative to current treatments.

Conclusions

MiR-210 holds significant promise for the early diagnosis and treatment of lung cancer, particularly in hypoxic tumors.
Its stability and detectability in biofluids position it as a valuable non-invasive biomarker.
Further research and standardization of detection methods are crucial for integrating miR-210 into clinical practice and personalized medicine strategies.

Keywords:

Biomarker HIF-1α Hypoxia Liquid biopsy Lung cancer miR-210 qRT- PCR β